Adaptimmune Therapeutics Plc Stock Current Ratio
| ADAP Stock | USD 1.24 0.09 7.83% |
Adaptimmune Therapeutics Plc fundamentals help investors to digest information that contributes to Adaptimmune Therapeutics' financial success or failures. It also enables traders to predict the movement of Adaptimmune Stock. The fundamental analysis module provides a way to measure Adaptimmune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptimmune Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 2.85 | 3.87 |
Adaptimmune | Current Ratio |
Adaptimmune Therapeutics Plc Company Current Ratio Analysis
Adaptimmune Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Adaptimmune Therapeutics Current Ratio | 4.00 X |
Most of Adaptimmune Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptimmune Therapeutics Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptimmune Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Adaptimmune Therapeutics is extremely important. It helps to project a fair market value of Adaptimmune Stock properly, considering its historical fundamentals such as Current Ratio. Since Adaptimmune Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adaptimmune Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adaptimmune Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Adaptimmune Current Ratio Historical Pattern
Today, most investors in Adaptimmune Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptimmune Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adaptimmune Therapeutics current ratio as a starting point in their analysis.
Adaptimmune Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Adaptimmune Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Adaptimmune Therapeutics Plc has a Current Ratio of 4.0 times. This is 37.46% higher than that of the Biotechnology sector and 42.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 85.19% lower than that of the firm.
Adaptimmune Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptimmune Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics of similar companies.Adaptimmune Therapeutics is currently under evaluation in current ratio category among related companies.
Adaptimmune Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptimmune Therapeutics from analyzing Adaptimmune Therapeutics' financial statements. These drivers represent accounts that assess Adaptimmune Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptimmune Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 126.0M | 767.9M | 584.3M | 235.4M | 159.5M | 151.5M | |
| Enterprise Value | 101.0M | 734.7M | 459.8M | 150.4M | 40.7M | 38.7M |
Adaptimmune Fundamentals
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.89) % | ||||
| Operating Margin | (215.83) % | ||||
| Current Valuation | 1.58 B | ||||
| Shares Outstanding | 255.56 M | ||||
| Shares Owned By Insiders | 0.38 % | ||||
| Shares Owned By Institutions | 66.73 % | ||||
| Number Of Shares Shorted | 3.52 M | ||||
| Price To Earning | (7.73) X | ||||
| Price To Book | 7.50 X | ||||
| Price To Sales | 4.92 X | ||||
| Revenue | 60.51 M | ||||
| Gross Profit | (100.58 M) | ||||
| EBITDA | (127.91 M) | ||||
| Net Income | (114.31 M) | ||||
| Cash And Equivalents | 199.67 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 25.23 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 4.00 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (141.43 M) | ||||
| Short Ratio | 2.76 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Price To Earnings To Growth | 0.11 X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 449 | ||||
| Beta | 2.44 | ||||
| Market Capitalization | 325.01 M | ||||
| Total Asset | 282.62 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 134.76 M | ||||
| Current Asset | 199.54 M | ||||
| Current Liabilities | 22.66 M | ||||
| Net Asset | 282.62 M |
About Adaptimmune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptimmune Therapeutics Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptimmune Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptimmune Therapeutics' short interest history, or implied volatility extrapolated from Adaptimmune Therapeutics options trading.
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.75 | VRDN | Viridian Therapeutics | PairCorr |
| 0.68 | FBIO | Fortress Biotech Financial Report 20th of May 2024 | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Adaptimmune Stock
| 0.72 | ACB | Aurora Cannabis Financial Report 12th of June 2024 | PairCorr |
| 0.54 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.42 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Adaptimmune Therapeutics Piotroski F Score and Adaptimmune Therapeutics Altman Z Score analysis. Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Adaptimmune Stock analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 0.3 | Quarterly Revenue Growth (0.98) | Return On Assets (0.28) | Return On Equity (1.88) |
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.